Natural compound for slowing rumen microorganism from decomposing amino acid and urea and application thereof

文档序号:1397071 发布日期:2020-03-03 浏览:36次 中文

阅读说明:本技术 一种减缓瘤胃微生物分解氨基酸和尿素的天然化合物及其用途 (Natural compound for slowing rumen microorganism from decomposing amino acid and urea and application thereof ) 是由 王加启 赵圣国 郑楠 刘思佳 张震宇 李松励 张养东 于 2018-08-24 设计创作,主要内容包括:本发明属于动物饲料添加剂的技术领域,具体涉及一种通过减缓瘤胃微生物分解氨基酸和尿素,减少氨氮生成量,提高瘤胃氮利用率的天然化合物。本发明主要涉及如下式I化合物及其药学上可接受的盐在制备氨基酸脱氨酶和脲酶抑制剂中的应用,<Image he="458" wi="700" file="DDA0001777091990000011.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>其中,R<Sub>1</Sub>、R<Sub>2</Sub>、R<Sub>3</Sub>、R<Sub>4</Sub>、R<Sub>5</Sub>相同或不同,彼此独立的选自H、或下列基团:C<Sub>1-12</Sub>烷基、C<Sub>3-20</Sub>环烷基、C<Sub>6-20</Sub>芳基、5-20元杂芳基。(The invention belongs to the technical field of animal feed additives, and particularly relates to a natural compound for reducing ammonia nitrogen generation amount and improving rumen nitrogen utilization rate by slowing down rumen microorganisms to decompose amino acid and urea. The invention mainly relates to an application of a compound shown in the following formula I and pharmaceutically acceptable salts thereof in preparing amino acid deaminase and urease inhibitors, wherein R is 1 、R 2 、R 3 、R 4 、R 5 Identical or different, independently of one another, from H or the following radicals: c 1‑12 Alkyl radical, C 3‑20 Cycloalkyl radical, C 6‑20 Aryl, 5-20 membered heteroaryl.)

1. A compound of formula I or a pharmaceutically acceptable salt thereof:

Figure FDA0001777091960000011

wherein R is1、R2、R3、R4、R5Identical or different, independently of one another, from H or the following radicals: c1-12Alkyl radical, C3-20Cycloalkyl radical, C6-20Aryl, 5-20 membered heteroaryl;

preferably, R2、R3、R4、R5Selected from H, R1Is selected from C1-3An alkyl group;

preferably, the compound of formula I is selected from biochanin a of formula:

Figure FDA0001777091960000012

2. a pharmaceutical composition comprising a compound of formula I as described in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is an amino acid deaminase and urease inhibitor, such as a rumen microbial amino acid deaminase and urease inhibitor.

4. The pharmaceutical composition of claim 2 or 3, wherein the pharmaceutical composition further comprises one or more additional active ingredients.

5. Pharmaceutical composition according to any of claims 2 to 4, wherein the other active ingredients are selected from other rumen microbial amino acid deaminase and/or urease inhibitors or compounds that enhance the inhibitory activity of the compounds of formula I.

6. Use of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament;

preferably, the medicament has an activity of inhibiting rumen microbial amino acid deaminase and/or urease.

7. Use according to claim 6, wherein the medicament is for inhibiting the degradation rate of amino acids (such as valine and/or lysine) (e.g. for slowing the decomposition of amino acids by ruminal microorganisms), or for inhibiting the production of ammonia nitrogen in the rumen, or for avoiding ruminal ammonia poisoning in ruminants, or for increasing the efficiency of ruminal nitrogen utilization, or for promoting ruminal fermentation.

8. The use according to claim 6 or 7, wherein the medicament promotes rumen fermentation with a 1.5% -2.5% increase in gas production; or the medicament inhibits the generation of ammonia nitrogen in rumen with an inhibition rate of 21-28%; alternatively, the drug inhibits the degradation rate of amino acids (such as valine and/or lysine) by 12% -18%.

9. A method of inhibiting microbial amino acid deaminase and/or urease for non-therapeutic purposes, such as inhibiting rumen microbial amino acid deaminase and/or urease activity, comprising administering a compound of formula I as described in claim 1, or a pharmaceutically acceptable salt thereof, to a ruminant animal.

10. A method of inhibiting microbial amino acid deaminase and/or urease for non-therapeutic purposes, such as inhibiting rumen microbial amino acid deaminase and/or urease activity, comprising administering a composition according to any one of claims 2-5 to a ruminant.

Technical Field

The invention belongs to the technical field of animal feed additives, and particularly relates to a natural compound for slowing rumen microorganisms from decomposing amino acid and urea and application thereof.

Background

Ruminant rumen microorganisms can degrade part of feed protein or other nitrogen-containing substances into ammonia nitrogen, and degrade the other part of feed protein into amino acids and polypeptides. The microorganism utilizes ammonia nitrogen, amino acid and polypeptide generated by decomposition to synthesize microbial protein again, and the microbial protein is utilized by animals. While the excess production of rumen ammonia nitrogen provides an inorganic nitrogen source for ruminant microorganisms, part of feed high-quality protein is degraded, so that feed protein is wasted, and the protein raw material is the part with the largest price proportion in the feed, so that the protein hydrolysis and the amino acid degradation in rumen show considerable economic loss in ruminant production. In addition, too fast decomposition of urea reduces its utilization rate, and too fast ammonia production is asynchronous with energy, reducing ammonia utilization. The generation of excessive ammonia nitrogen is easy to cause environmental pollution caused by high urinary nitrogen emission, and meanwhile, the excessive ammonia enters blood through the rumen wall, so that the ammonia stress of animal organisms and even ammonia poisoning are easily caused, and the animal health is harmed.

Compared with the traditional feed additive, the natural extract feed additive has the advantages of naturalness, multiple functions, sustainability and the like, has the characteristics of multiple components and multiple functions, and has a plurality of advantages and characteristics which are the core for replacing the traditional feed additive. The natural extract feed additive can better accord with the rule that the functions of animal organisms are mutually coordinated and integrally unified, the action is more comprehensive, and simultaneously, the multi-component synergistic effect ensures that the content of a certain specific component is lower, the toxicity (metabolic toxicity, teratogenicity, carcinogenicity and mutation capacity) of the feed additive is further weakened or eliminated after processing and processing, no obvious side effect is generated on animals, the drug resistance is not easy to generate, and the feed additive is suitable for long-term use. The active ingredients of the natural extract are natural products, most of the active ingredients are inherent ingredients of the feed, can be degraded by animals in the process of exerting the adjusting effect, have less residual quantity in animal products, do not bring harm to the ecological environment and have good safety. Natural, organic and residue-free are the development directions of future feed additives. The natural feed additive has wide market prospect as a green feed additive.

However, how to use natural compounds to solve the above technical problems is a difficult point and a focus of the current research.

Disclosure of Invention

In order to solve the problems in the prior art, the invention provides a compound shown as the following formula I or a pharmaceutically acceptable salt thereof:

Figure BDA0001777091970000021

wherein R is1、R2、R3、R4、R5Identical or different, independently of one another, from H or the following radicals: c1-12Alkyl radical, C3-20Cycloalkyl radical, C6-20Aryl, 5-20 membered heteroaryl.

According to an embodiment of the invention, R in the compound of formula I2、R3、R4、R5Selected from H, R1Is selected from C1-3An alkyl group.

As an example, the compound of formula I is selected from biochanin a represented by the following formula:

Figure BDA0001777091970000022

the invention also provides a pharmaceutical composition which comprises the compound shown in the formula I and pharmaceutically acceptable auxiliary materials.

According to an embodiment of the invention, the pharmaceutical composition is an amino acid deaminase and/or urease inhibitor, e.g. a rumen microbial amino acid deaminase and/or urease inhibitor.

According to the invention, the mass fraction of the compound shown in the formula I in the pharmaceutical composition is 1-99%, preferably 10-90%, and further preferably 20-80%.

Optionally, the pharmaceutical composition may further comprise one or more other active ingredients.

According to the invention, the further active ingredient is selected from other rumen microorganisms amino acid deaminase and/or urease inhibitors, or compounds which enhance the inhibitory activity of the compounds of formula I, such as acetohydroxamic acid.

The invention also provides application of the compound shown in the formula I or pharmaceutically acceptable salt thereof in preparing a medicament.

Preferably, the medicament has an activity of inhibiting rumen microbial amino acid deaminase and/or urease.

Preferably, the medicament is for inhibiting the degradation rate of amino acids, for example for slowing the decomposition of amino acids by rumen microorganisms.

Preferably, the medicament is for inhibiting the production of ammonia nitrogen in the rumen.

Preferably, the medicament is for use in avoiding ruminal ammonia poisoning in ruminants.

Preferably, the medicament is for increasing the efficiency of rumen nitrogen utilization.

Preferably, the medicament is for promoting rumen fermentation.

According to the present invention, the inhibitory activity of the drug against urease, such as rumen microbial urease, was 340.82 μmol/L as the IC50 value.

According to the invention, the medicine can promote rumen fermentation, and the gas production is increased by 1.5-2.5%.

According to the invention, the medicine can inhibit the generation of ammonia nitrogen in rumen, and the inhibition rate is 21-28%.

According to the present invention, the drug can inhibit the degradation rate of amino acids (such as valine and/or lysine) by 12% to 18%.

The present invention also provides a method of inhibiting microbial amino acid deaminase and/or urease for non-therapeutic purposes, such as a method of inhibiting rumen microbial amino acid deaminase and/or urease activity, comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to a ruminant animal.

The present invention also provides a method of inhibiting microbial amino acid deaminase and/or urease for non-therapeutic purposes, such as a method of inhibiting rumen microbial amino acid deaminase and/or urease activity, comprising administering the pharmaceutical composition to a ruminant.

Advantageous effects

The inventor of the application unexpectedly finds that the compound shown in the formula I can simultaneously slow down the decomposition speed of amino acid and urea by rumen microorganisms, thereby avoiding feed waste and rumen ammonia poisoning of ruminants and improving the utilization efficiency of rumen nitrogen.

Definition and description of terms

Unless defined otherwise below, all terms herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. If there are multiple definitions of terms herein, the following definitions apply.

The term "C1-12Alkyl is understood to mean a straight-chain or branched, saturated monovalent hydrocarbon radical having from 1 to 12 carbon atoms, preferably C1-10An alkyl group. "C1-10Alkyl "is understood to preferably mean a straight-chain or branched, saturated monovalent hydrocarbon radical having 1,2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-ethylpropyl, 1, 2-dimethylpropyl, neopentyl, 1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-methylpentyl, 2-ethylpropyl, 1-isobutylpentyl, tert-butyl, isopentyl, tert-butyl, 2-methylbutyl, 1-methylpentyl, 1-dimethylpEthyl butyl, 3-dimethylbutyl, 2-dimethylbutyl, 1-dimethylbutyl, 2, 3-dimethylbutyl, 1, 3-dimethylbutyl or 1, 2-dimethylbutyl, and the like, or isomers thereof. In particular, the radicals have 1,2, 3, 4, 5, 6 carbon atoms ("C)1-6Alkyl groups) such as methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, tert-butyl, more particularly groups having 1,2 or 3 carbon atoms ("C)1-3Alkyl groups) such as methyl, ethyl, n-propyl or isopropyl.

The term "C3-20Cycloalkyl is understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbon ring having 3 to 20 carbon atoms, preferably "C3-10Cycloalkyl groups ". The term "C3-10Cycloalkyl "is understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbon ring having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. Said C is3-10Cycloalkyl groups may be monocyclic hydrocarbon groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, or bicyclic hydrocarbon groups such as decalin rings.

The term "C6-20Aryl "is understood to preferably mean a mono-, bi-or tricyclic hydrocarbon ring having a monovalent or partially aromatic character with 6 to 20 carbon atoms, preferably" C6-14Aryl ". The term "C6-14Aryl "is to be understood as preferably meaning a mono-, bi-or tricyclic hydrocarbon ring having a monovalent or partially aromatic character with 6, 7, 8, 9, 10, 11, 12, 13 or 14 carbon atoms (" C6-14Aryl group "), in particular a ring having 6 carbon atoms (" C6Aryl "), such as phenyl; or biphenyl, or is a ring having 9 carbon atoms ("C9Aryl), such as indanyl or indenyl, or a ring having 10 carbon atoms ("C10Aryl radicals), such as tetralinyl, dihydronaphthyl or naphthyl, or rings having 13 carbon atoms ("C13Aryl radicals), such as the fluorenyl radical, or a ring having 14 carbon atoms ("C)14Aryl), such as anthracenyl.

The term "5-20 membered heteroaryl" is understood to include such monovalent monocyclic, bicyclic or tricyclic aromatic ring systems: having 5 to 20 ring atoms and comprising 1 to 5 heteroatoms independently selected from N, O, S, such as "5-14 membered heteroaryl".

The term "5-14 membered heteroaryl" is understood to include such monovalent monocyclic, bicyclic or tricyclic aromatic ring systems: which has 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, in particular 5 or 6 or 9 or 10 carbon atoms, and which contains 1 to 5, preferably 1 to 3 heteroatoms selected independently of one another from N, O, S and, in addition, can be benzo-fused in each case. In particular, heteroaryl is selected from thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl and the like and their benzo derivatives, such as benzofuryl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl and the like; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like, and benzo derivatives thereof, such as quinolyl, quinazolinyl, isoquinolyl, and the like; or azocinyl, indolizinyl, purinyl and the like and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and the like.

Unless otherwise indicated, heterocyclyl, heteroaryl or heteroarylene include all possible isomeric forms thereof, e.g., positional isomers thereof. Thus, for some illustrative, non-limiting examples, pyridyl or pyridinylene includes pyridin-2-yl, pyridinylene-2-yl, pyridin-3-yl, pyridinylene-3-yl, pyridin-4-yl, and pyridinylene-4-yl; thienyl or thienylene includes thien-2-yl, thien-3-yl and thien-3-yl.

The term "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

According to the invention, examples of said amino acids may be valine and/or lysine.

Drawings

FIG. 1 is a graph showing the effect of biochanin A on rumen gas production during passage.

FIG. 2 shows the effect of biochanin A on ammonia nitrogen yield during passage.

FIG. 3 is a graph of the effect of biochanin A on total amino acid degradation rate at different time points.

FIG. 4 is a graph of the effect of biochanin A on valine and lysine degradation rates at various time points.

Detailed Description

The compounds of the general formula and the preparation and use thereof according to the present invention will be described in further detail with reference to the following examples. The following examples are merely illustrative and explanatory of the present invention and should not be construed as limiting the scope of the invention. All the technologies realized based on the above-mentioned contents of the present invention are covered in the protection scope of the present invention.

Unless otherwise indicated, the raw materials and reagents used in the following examples are all commercially available products or can be prepared by known methods.

1. Laboratory apparatus

Amino acid analyzer (Hitachi L-8900)

Enzyme mark instrument (Thermo Electron Varioskan Flash G-282)

Barometer (ConST 211)

2. Primary reagent

(1)50mmol/L urea buffer solution: 0.3g of urea was weighed, dissolved in deionized water and brought to a volume of 100 mL.

(2) Phenol-sodium nitroprusside solution: 10g of phenol and 50mg of sodium nitroprusside (also known as sodium nitroferricyanide) are weighed out, dissolved in deionized water and brought to a volume of 1L. Placing into brown bottle, and storing at 4 deg.C for one month.

(3) Alkaline sodium hypochlorite solution: 5g of NaOH and 8.4mL of NaClO solution were dissolved in deionized water and brought to 1L. Placing into brown bottle, and storing at 4 deg.C for one month.

(4)10mmol/L NH4Standard solution of Cl: scale 0.5349NH4And dissolving Cl in deionized water and fixing the volume to 1L.

(5)50mmol/L HEPES buffer solution (pH 7.5): 1.19g of sodium 4-hydroxyethyl piperazine sulfonate (HEPES) was weighed, dissolved in deionized water and made to volume of 100mL, and the pH was adjusted to 7.5 with NaOH.

13页详细技术资料下载
上一篇:一种医用注射器针头装配设备
下一篇:一种EGFR激酶抑制剂及其制备方法和应用

网友询问留言

已有0条留言

还没有人留言评论。精彩留言会获得点赞!

精彩留言,会给你点赞!

技术分类